{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:42:41Z","timestamp":1792154561571,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In randomized controlled trials, add-on cannabidiol (CBD) has been shown to reduce seizure frequency in patients with Lennox-Gastaut syndrome, Dravet syndrome and Tuberous sclerosis complex. Real-world studies provide insights into the drug\u2019s profile in other off-label indications. This study evaluated factors predicting efficacy, retention, and tolerability of add-on CBD used for off-label treatment in clinical practice for patients with refractory focal-onset, genetic generalised, and other unclassified epilepsies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective cohort study recruiting all patients who had started CBD between 2019 and 2023 for off-label treatment at six German epilepsy centres. Data on baseline and follow-up were obtained from patients\u2019 medical records.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 108 patients (mean age 27.3; median 36; range 1.4\u201368 years, 56 male) were treated with CBD. At three months, 42 (38.9% considering all 108 patients that started CBD) reported at least a 50% reduction in seizures, including 28 patients (25.9%) with a 50\u201374% reduction, and 14 (13%) with a reduction of 75\u201399%. Among those 48 patients experiencing tonic-clonic seizures (TCS), at least 50% response was reported by 45.8%, and eight (16.7%) patients were free of TCS. Sex, age, epilepsy syndrome, concomitant clobazam (CLB) use, and the number of concomitant or previous ASMs were not predictive of response. Mean seizure days per month significantly decreased from a mean of 16.8 (median: 13.5) to 14.5 (median 10, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). The probability of patients remaining on CBD treatment was 85.2% (<jats:italic>n<\/jats:italic>\u2009=\u200992\/108, 16 discontinuations) at three months, 73.5% at six months and 61.1% at twelve months; retention was better in children or adolescents compared to adults (log-rank <jats:italic>p<\/jats:italic>\u2009=\u20090.014). Using the CGI-C for overall impression, 69 (63.0%) patients were rated as very much, much, or minimally improved; for behaviour, 60 (55.6%) reported within this range of improvement. TEAEs were reported in 41 (38%) patients. The most frequent were diarrhoea (<jats:italic>n<\/jats:italic>\u2009=\u200915), sedation (<jats:italic>n<\/jats:italic>\u2009=\u200913), and nausea and vomiting (<jats:italic>n<\/jats:italic>\u2009=\u20097).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our results suggest CBD to be an effective ASM, with 50% responder rates similar to those observed in regulatory trials for other ASMs licensed in focal epilepsies. Its off-label use in refractory focal-onset, genetic generalised, and other unclassified epilepsies seems to be safe and well-tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s42466-025-00408-w","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:40:00Z","timestamp":1753202400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies"],"prefix":"10.1186","volume":"7","author":[{"given":"Marie","family":"Hollander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin Alexandra","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Knake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"von Podewils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kurlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Immisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schubert-Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"5","key":"408_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan, P., & Brodie, M. J. (2000). Early identification of refractory epilepsy. New England Journal of Medicine, 342(5), 314\u2013319.","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"408_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMra1004418","volume":"365","author":"P Kwan","year":"2011","unstructured":"Kwan, P., Schachter, S. C., & Brodie, M. J. (2011). Drug-resistant epilepsy. New England Journal of Medicine, 365(10), 919\u2013926.","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"408_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2165\/00019053-200826060-00002","volume":"26","author":"A Strzelczyk","year":"2008","unstructured":"Strzelczyk, A., Reese, J. P., Dodel, R., et al. (2008). Cost of epilepsy: A systematic review. Pharmacoeconomics, 26(6), 463\u2013476.","journal-title":"Pharmacoeconomics"},{"key":"408_CR4","doi-asserted-by":"publisher","first-page":"109255","DOI":"10.1016\/j.yebeh.2023.109255","volume":"144","author":"LM Willems","year":"2023","unstructured":"Willems, L. M., Z\u00f6llner, J. P., Hamann, L., et al. (2023). Unemployment and early retirement among patients with epilepsy - A study on predictors, resilience factors and occupational reintegration measures. Epilepsy & Behavior, 144, 109255. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109255","journal-title":"Epilepsy &amp; Behavior"},{"issue":"6","key":"408_CR5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/epi.17229","volume":"63","author":"LM Willems","year":"2022","unstructured":"Willems, L. M., Hochbaum, M., Z\u00f6llner, J. P., et al. (2022). Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020. Epilepsia, 63(6), 1591\u20131602. https:\/\/doi.org\/10.1111\/epi.17229","journal-title":"Epilepsia"},{"issue":"Pt 2","key":"408_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/brain\/awq378","volume":"134","author":"A Neligan","year":"2011","unstructured":"Neligan, A., Bell, G. S., Johnson, A. L., et al. (2011). The long-term risk of premature mortality in people with epilepsy. Brain, 134(Pt 2), 388\u2013395. https:\/\/doi.org\/10.1093\/brain\/awq378","journal-title":"Brain"},{"issue":"12","key":"408_CR7","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1007\/s00415-020-10065-5","volume":"267","author":"K Frey","year":"2020","unstructured":"Frey, K., Z\u00f6llner, J. P., Knake, S., et al. (2020). Risk incidence of fractures and injuries: A multicenter video-EEG study of 626 generalized convulsive seizures. Journal of Neurology, 267(12), 3632\u20133642. https:\/\/doi.org\/10.1007\/s00415-020-10065-5","journal-title":"Journal of Neurology"},{"issue":"1","key":"408_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s42466-023-00265-5","volume":"5","author":"K Siebenbrodt","year":"2023","unstructured":"Siebenbrodt, K., Willems, L. M., von Podewils, F., et al. (2023). Determinants of quality of life in adults with epilepsy: A multicenter, cross-sectional study from Germany. Neurol Res Pract, 5(1), 41. https:\/\/doi.org\/10.1186\/s42466-023-00265-5","journal-title":"Neurol Res Pract"},{"issue":"4","key":"408_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ana.21064","volume":"62","author":"AL Luciano","year":"2007","unstructured":"Luciano, A. L., & Shorvon, S. D. (2007). Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Annals of Neurology, 62(4), 375\u2013381.","journal-title":"Annals of Neurology"},{"issue":"3","key":"408_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1528-1167.2010.02929.x","volume":"52","author":"B Callaghan","year":"2011","unstructured":"Callaghan, B., Schlesinger, M., Rodemer, W., et al. (2011). Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia, 52(3), 619\u2013626. https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02929.x","journal-title":"Epilepsia"},{"issue":"1","key":"408_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s42466-023-00288-y","volume":"5","author":"L Mann","year":"2023","unstructured":"Mann, L., Rosenow, F., Strzelczyk, A., et al. (2023). The impact of referring patients with drug-resistant focal epilepsy to an epilepsy center for presurgical diagnosis. Neurol Res Pract, 5(1), 65. https:\/\/doi.org\/10.1186\/s42466-023-00288-y","journal-title":"Neurol Res Pract"},{"issue":"20","key":"408_CR12","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky, O., Patel, A. D., Cross, J. H., et al. (2018). Effect of Cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine, 378(20), 1888\u20131897. https:\/\/doi.org\/10.1056\/NEJMoa1714631","journal-title":"New England Journal of Medicine"},{"issue":"10125","key":"408_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/s0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele, E. A., Marsh, E. D., French, J. A., et al. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 391(10125), 1085\u20131096. https:\/\/doi.org\/10.1016\/s0140-6736(18)30136-3","journal-title":"Lancet"},{"key":"408_CR14","doi-asserted-by":"publisher","unstructured":"Miller, I., Scheffer, I. E., Gunning, B., et al. (2020 Mar). Dose-Ranging effect of adjunctive oral Cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: A randomized clinical trial. JAMA Neurol, 2. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0073","DOI":"10.1001\/jamaneurol.2020.0073"},{"issue":"21","key":"408_CR15","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky, O., Cross, J. H., Laux, L., et al. (2017). Trial of Cannabidiol for Drug-Resistant seizures in the Dravet syndrome. New England Journal of Medicine, 376(21), 2011\u20132020. https:\/\/doi.org\/10.1056\/NEJMoa1611618","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"408_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","volume":"78","author":"EA Thiele","year":"2021","unstructured":"Thiele, E. A., Bebin, E. M., Bhathal, H., et al. (2021). Add-on Cannabidiol treatment for Drug-Resistant seizures in tuberous sclerosis complex: A Placebo-Controlled randomized clinical trial. JAMA Neurol, 78(3), 285\u2013292. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4607","journal-title":"JAMA Neurol"},{"issue":"1","key":"408_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s42466-024-00323-6","volume":"6","author":"L Lappe","year":"2024","unstructured":"Lappe, L., Hertzberg, C., Knake, S., et al. (2024). A multicenter, matched case-control analysis comparing burden of illness among patients with tuberous sclerosis complex related epilepsy, generalized idiopathic epilepsy, and focal epilepsy in Germany. Neurol Res Pract, 6(1), 29. https:\/\/doi.org\/10.1186\/s42466-024-00323-6","journal-title":"Neurol Res Pract"},{"key":"408_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.yebeh.2016.10.025","volume":"66","author":"BJ Steinhoff","year":"2017","unstructured":"Steinhoff, B. J., Staack, A. M., & Hillenbrand, B. C. (2017). Randomized controlled antiepileptic drug trials miss almost all patients with ongoing seizures. Epilepsy & Behavior, 66, 45\u201348. https:\/\/doi.org\/10.1016\/j.yebeh.2016.10.025","journal-title":"Epilepsy & Behavior"},{"issue":"2","key":"408_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1212\/WNL.49.2.333","volume":"49","author":"MC Walker","year":"1997","unstructured":"Walker, M. C., & Sander, J. W. (1997). Difficulties in extrapolating from clinical trial data to clinical practice: The case of antiepileptic drugs. Neurology, 49(2), 333\u2013337.","journal-title":"Neurology"},{"issue":"4","key":"408_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14737175.2024.2326606","volume":"24","author":"S Matricardi","year":"2024","unstructured":"Matricardi, S., Scorrano, G., Prezioso, G., et al. (2024). The latest advances in the Pharmacological management of focal epilepsies in children: A narrative review. Expert Review of Neurotherapeutics, 24(4), 371\u2013381. https:\/\/doi.org\/10.1080\/14737175.2024.2326606","journal-title":"Expert Review of Neurotherapeutics"},{"key":"408_CR21","doi-asserted-by":"publisher","first-page":"109653","DOI":"10.1016\/j.yebeh.2024.109653","volume":"152","author":"J Tong","year":"2024","unstructured":"Tong, J., Ji, T., Liu, T., et al. (2024). Efficacy and safety of six new Antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis. Epilepsy & Behavior, 152, 109653. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109653","journal-title":"Epilepsy & Behavior"},{"key":"408_CR22","doi-asserted-by":"publisher","first-page":"175628642312077","DOI":"10.1177\/17562864231207755","volume":"16","author":"S Liu","year":"2023","unstructured":"Liu, S., He, Z., & Li, J. (2023). Long-term efficacy and adverse effects of Cannabidiol in adjuvant treatment of drug-resistant epilepsy: A systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders, 16, 17562864231207755. https:\/\/doi.org\/10.1177\/17562864231207755","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"3","key":"408_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","volume":"35","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi, S., Trinka, E., Striano, P., et al. (2021). Highly purified Cannabidiol for epilepsy treatment: A systematic review of epileptic conditions beyond Dravet syndrome and Lennox-Gastaut syndrome. Cns Drugs, 35(3), 265\u2013281. https:\/\/doi.org\/10.1007\/s40263-021-00807-y","journal-title":"Cns Drugs"},{"issue":"7624","key":"408_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm, E., Altman, D. G., Egger, M., et al. (2007). Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Bmj, 335(7624), 806\u2013808. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD","journal-title":"Bmj"},{"issue":"4","key":"408_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer, I. E., Berkovic, S., Capovilla, G., et al. (2017). ILAE classification of the epilepsies: Position paper of the ILAE commission for classification and terminology. Epilepsia, 58(4), 512\u2013521. https:\/\/doi.org\/10.1111\/epi.13709","journal-title":"Epilepsia"},{"issue":"4","key":"408_CR26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher, R. S., Cross, J. H., French, J. A., et al. (2017). Operational classification of seizure types by the international league against epilepsy: Position paper of the ILAE commission for classification and terminology. Epilepsia, 58(4), 522\u2013530. https:\/\/doi.org\/10.1111\/epi.13670","journal-title":"Epilepsia"},{"issue":"6","key":"408_CR27","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/epi.17241","volume":"63","author":"N Specchio","year":"2022","unstructured":"Specchio, N., Wirrell, E. C., Scheffer, I. E., et al. (2022). International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE task force on nosology and definitions. Epilepsia, 63(6), 1398\u20131442. https:\/\/doi.org\/10.1111\/epi.17241","journal-title":"Epilepsia"},{"issue":"6","key":"408_CR28","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/epi.17239","volume":"63","author":"SM Zuberi","year":"2022","unstructured":"Zuberi, S. M., Wirrell, E., Yozawitz, E., et al. (2022). ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE task force on nosology and definitions. Epilepsia, 63(6), 1349\u20131397. https:\/\/doi.org\/10.1111\/epi.17239","journal-title":"Epilepsia"},{"key":"408_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","volume":"123","author":"H Northrup","year":"2021","unstructured":"Northrup, H., Aronow, M. E., Bebin, E. M., et al. (2021). Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatric Neurology, 123, 50\u201366. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2021.07.011","journal-title":"Pediatric Neurology"},{"key":"408_CR30","doi-asserted-by":"publisher","first-page":"110302","DOI":"10.1016\/j.yebeh.2025.110302","volume":"166","author":"A Strzelczyk","year":"2025","unstructured":"Strzelczyk, A., Schubert-Bast, S., von Podewils, F., et al. (2025). Real-world experience of Cannabidiol in conjunction with clobazam for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome: Results from a retrospective multicentre chart review in Germany. Epilepsy & Behavior, 166, 110302. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110302","journal-title":"Epilepsy & Behavior"},{"key":"408_CR31","doi-asserted-by":"publisher","unstructured":"Beniczky, S., Trinka, E., Wirrell, E., et al. (2025). Updated classification of epileptic seizures: Position paper of the international league against epilepsy. Epilepsia,66(6),1804\u20131823. https:\/\/doi.org\/10.1111\/epi.18338","DOI":"10.1111\/epi.18338"},{"issue":"2","key":"408_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/epi4.12699","volume":"8","author":"F Kuhne","year":"2023","unstructured":"K\u00fchne, F., Becker, L. L., Bast, T., et al. (2023). Real-world data on Cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. Epilepsia Open, 8(2), 360\u2013370. https:\/\/doi.org\/10.1002\/epi4.12699","journal-title":"Epilepsia Open"},{"key":"408_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.seizure.2023.09.015","volume":"112","author":"C Espinosa-Jovel","year":"2023","unstructured":"Espinosa-Jovel, C., Riveros, S., Bolanos-Almeida, C., et al. (2023). Real-world evidence on the use of Cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex. Seizure, 112, 72\u201376. https:\/\/doi.org\/10.1016\/j.seizure.2023.09.015","journal-title":"Seizure"},{"key":"408_CR34","doi-asserted-by":"publisher","first-page":"107300","DOI":"10.1016\/j.eplepsyres.2024.107300","volume":"200","author":"JP Barnes","year":"2024","unstructured":"Barnes, J. P., Dial, H., Owens, W., et al. (2024). Adherence and discontinuation of prescription Cannabidiol for the management of seizure disorders at an integrated care center. Epilepsy Research, 200, 107300. https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107300","journal-title":"Epilepsy Research"},{"key":"408_CR35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/epi.12284","volume":"54","author":"J Novy","year":"2013","unstructured":"Novy, J., Bartolini, E., Bell, G. S., et al. (2013). Long term retention of lacosamide in a large cohort of people with medically refractory epilepsy: A single centre evaluation. Epilepsy Research, 106(1-2), 250\u2013256.","journal-title":"Epilepsia"},{"issue":"7","key":"408_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.seizure.2012.05.005","volume":"21","author":"L Flores","year":"2012","unstructured":"Flores, L., Kemp, S., Colbeck, K., et al. (2012). Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: A multicentre study in epilepsy clinics in the united Kingdom (UK). Seizure-European Journal of Epilepsy, 21(7), 512\u2013517. https:\/\/doi.org\/10.1016\/j.seizure.2012.05.005","journal-title":"Seizure-European Journal of Epilepsy"},{"issue":"9566","key":"408_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., et al. (2007). The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial. Lancet, 369(9566), 1000\u20131015. https:\/\/doi.org\/10.1016\/S0140-6736(07)60460-7","journal-title":"Lancet"},{"issue":"1\u20132","key":"408_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.eplepsyres.2011.04.012","volume":"96","author":"CB Catarino","year":"2011","unstructured":"Catarino, C. B., Bartolini, E., Bell, G. S., et al. (2011). The long-term retention of Zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. Epilepsy Research, 96(1\u20132), 39\u201344. https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.04.012","journal-title":"Epilepsy Research"},{"issue":"3","key":"408_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1059-1311(02)00258-3","volume":"12","author":"T Betts","year":"2003","unstructured":"Betts, T., Yarrow, H., Greenhill, L., et al. (2003). Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study. Seizure, 12(3), 136\u2013140.","journal-title":"Seizure"},{"issue":"12","key":"408_CR40","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1111\/epi.17087","volume":"62","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk, A., Zaveta, C., von Podewils, F., et al. (2021). Long-term efficacy, tolerability, and retention of Brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up. Epilepsia, 62(12), 2994\u20133004. https:\/\/doi.org\/10.1111\/epi.17087","journal-title":"Epilepsia"},{"issue":"3","key":"408_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/17512433.2018.1421066","volume":"11","author":"LM Willems","year":"2018","unstructured":"Willems, L. M., Z\u00f6llner, J. P., Paule, E., et al. (2018). Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: Systematic review of current evidence. Expert Rev Clin Pharmacol, 11(3), 309\u2013324. https:\/\/doi.org\/10.1080\/17512433.2018.1421066","journal-title":"Expert Rev Clin Pharmacol"},{"key":"408_CR42","doi-asserted-by":"publisher","first-page":"1120150","DOI":"10.3389\/fneur.2023.1120150","volume":"14","author":"C Liguori","year":"2023","unstructured":"Liguori, C., Santamarina, E., Strzelczyk, A., et al. (2023). Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: Evidence from the PERMIT study. Frontiers in Neurology, 14, 1120150. https:\/\/doi.org\/10.3389\/fneur.2023.1120150","journal-title":"Frontiers in Neurology"},{"issue":"9","key":"408_CR43","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40263-023-01033-4","volume":"37","author":"V Villanueva","year":"2023","unstructured":"Villanueva, V., Laloyaux, C., D\u2019Souza, W., et al. (2023). Effectiveness and tolerability of 12-Month Brivaracetam in the real world: EXPERIENCE, an international pooled analysis of individual patient records. CNS Drugs, 37(9), 819\u2013835. https:\/\/doi.org\/10.1007\/s40263-023-01033-4","journal-title":"Cns Drugs"},{"key":"408_CR44","doi-asserted-by":"publisher","unstructured":"Roberti, R., Assenza, G., Bisulli, F., et al. (2024). Adjunctive cenobamate in people with focal onset seizures: Insights from the Italian expanded access program. Epilepsia, 65(10), 2909\u20132922. https:\/\/doi.org\/10.1111\/epi.18091","DOI":"10.1111\/epi.18091"},{"issue":"4","key":"408_CR45","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/epi4.12992","volume":"9","author":"BJ Steinhoff","year":"2024","unstructured":"Steinhoff, B. J., Georgiou, D., & Intravooth, T. (2024). The cenobamate KORK study-A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and Brivaracetam. Epilepsia Open, 9(4), 1502\u20131514. https:\/\/doi.org\/10.1002\/epi4.12992","journal-title":"Epilepsia Open"},{"issue":"2","key":"408_CR46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","volume":"82","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi, S., Trinka, E., Zaccara, G., et al. (2022). Third-Generation Antiseizure medications for adjunctive treatment of Focal-Onset seizures in adults: A systematic review and network Meta-analysis. Drugs, 82(2), 199\u2013218. https:\/\/doi.org\/10.1007\/s40265-021-01661-4","journal-title":"Drugs"},{"issue":"3","key":"408_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40263-025-01158-8","volume":"39","author":"A Strzelczyk","year":"2025","unstructured":"Strzelczyk, A., von Podewils, F., Hamer, H. M., et al. (2025). Post-marketing experience with cenobamate in the treatment of focal epilepsies: A multicentre cohort study. CNS Drugs, 39(3), 321\u2013331. https:\/\/doi.org\/10.1007\/s40263-025-01158-8","journal-title":"Cns Drugs"},{"issue":"4","key":"408_CR48","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/epi.16476","volume":"61","author":"S Thieffry","year":"2020","unstructured":"Thieffry, S., Klein, P., Baulac, M., et al. (2020). Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs. Epilepsia, 61(4), 595\u2013609. https:\/\/doi.org\/10.1111\/epi.16476","journal-title":"Epilepsia"},{"key":"408_CR49","doi-asserted-by":"publisher","first-page":"109512","DOI":"10.1016\/j.yebeh.2023.109512","volume":"149","author":"M Azevedo","year":"2023","unstructured":"Azevedo, M., & Benbadis, S. R. (2023). Efficacy of highly purified Cannabidiol (CBD) in typical absence seizures: A pilot study. Epilepsy & Behavior, 149, 109512. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109512","journal-title":"Epilepsy & Behavior"},{"issue":"4","key":"408_CR50","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/ejn.15096","volume":"55","author":"AJ Roebuck","year":"2022","unstructured":"Roebuck, A. J., Greba, Q., Onofrychuk, T. J., et al. (2022). Dissociable changes in Spike and wave discharges following exposure to injected cannabinoids and smoked cannabis in genetic absence epilepsy rats from Strasbourg. European Journal of Neuroscience, 55(4), 1063\u20131078. https:\/\/doi.org\/10.1111\/ejn.15096","journal-title":"European Journal of Neuroscience"},{"key":"408_CR51","doi-asserted-by":"publisher","unstructured":"Strzelczyk, A., von Stuckrad-Barre, S., Kurlemann, G., et al. (2025). Off-label-Use von anfallssuppressiver und immunsuppressiver Medikation bei Epilepsien. Clinical Epileptology, 38(1), 54\u201362.. https:\/\/doi.org\/10.1007\/s10309-024-00735-z","DOI":"10.1007\/s10309-024-00735-z"},{"key":"408_CR52","doi-asserted-by":"publisher","unstructured":"Reddy, D. S. Therapeutic and clinical foundations of Cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. Experimental Neurology. 2023 2023\/01\/01\/;359:114237. https:\/\/doi.org\/10.1016\/j.expneurol.2022.114237","DOI":"10.1016\/j.expneurol.2022.114237"},{"key":"408_CR53","doi-asserted-by":"publisher","first-page":"110988","DOI":"10.1016\/j.cbi.2024.110988","volume":"394","author":"M Osman","year":"2024","unstructured":"Osman, M., Khalil, J., El-Bahri, M., et al. (2024). Decoding epilepsy treatment: A comparative evaluation contrasting Cannabidiol pharmacokinetics in adult and paediatric populations. Chem Biol Interact, 394, 110988. https:\/\/doi.org\/10.1016\/j.cbi.2024.110988","journal-title":"Chem Biol Interact"},{"key":"408_CR54","doi-asserted-by":"publisher","first-page":"109159","DOI":"10.1016\/j.yebeh.2023.109159","volume":"141","author":"D Georgieva","year":"2023","unstructured":"Georgieva, D., Langley, J., Hartkopf, K., et al. (2023). Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex\u00ae (cannabidiol) in patients with refractory epilepsy. Epilepsy & Behavior, 141, 109159. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109159","journal-title":"Epilepsy & Behavior"},{"key":"408_CR55","doi-asserted-by":"publisher","first-page":"673135","DOI":"10.3389\/fneur.2021.673135","volume":"12","author":"LF Iannone","year":"2021","unstructured":"Iannone, L. F., Arena, G., Battaglia, D., et al. (2021). Results from an Italian expanded access program on Cannabidiol treatment in highly refractory Dravet syndrome and Lennox-Gastaut syndrome. Frontiers in Neurology, 12, 673135. https:\/\/doi.org\/10.3389\/fneur.2021.673135","journal-title":"Frontiers in Neurology"},{"key":"408_CR56","doi-asserted-by":"publisher","first-page":"107862","DOI":"10.1016\/j.yebeh.2021.107862","volume":"117","author":"TE Gaston","year":"2021","unstructured":"Gaston, T. E., Ampah, S. B., Martina Bebin, E., et al. (2021). Long-term safety and efficacy of highly purified Cannabidiol for treatment refractory epilepsy. Epilepsy & Behavior, 117, 107862. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107862","journal-title":"Epilepsy & Behavior"},{"issue":"17","key":"408_CR57","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","volume":"78","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi, S., Brigo, F., Trinka, E., et al. (2018). Efficacy and safety of Cannabidiol in epilepsy: A systematic review and Meta-Analysis. Drugs, 78(17), 1791\u20131804. https:\/\/doi.org\/10.1007\/s40265-018-0992-5","journal-title":"Drugs"},{"issue":"3","key":"408_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40263-020-00708-6","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi, S., Brigo, F., Trinka, E., et al. (2020). Adjunctive Cannabidiol in patients with Dravet syndrome: A systematic review and Meta-Analysis of efficacy and safety.  CNS Drugs, 34(3), 229\u2013241. https:\/\/doi.org\/10.1007\/s40263-020-00708-6","journal-title":"Cns Drugs"},{"key":"408_CR59","doi-asserted-by":"publisher","first-page":"114238","DOI":"10.1016\/j.expneurol.2022.114238","volume":"359","author":"A Talwar","year":"2023","unstructured":"Talwar, A., Estes, E., Aparasu, R., et al. (2023). Clinical efficacy and safety of Cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Experimental Neurology, 359, 114238. https:\/\/doi.org\/10.1016\/j.expneurol.2022.114238","journal-title":"Experimental Neurology"},{"issue":"10","key":"408_CR60","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk, A., & Schubert-Bast, S. (2022). Psychobehavioural and cognitive adverse events of Anti-Seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs, 36(10), 1079\u20131111. https:\/\/doi.org\/10.1007\/s40263-022-00955-9","journal-title":"Cns Drugs"},{"issue":"5","key":"408_CR61","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/epi.17930","volume":"65","author":"T Hannon","year":"2024","unstructured":"Hannon, T., Fernandes, K. M., Wong, V., et al. (2024). Over- and underreporting of seizures: How big is the problem? Epilepsia, 65(5), 1406\u20131414. https:\/\/doi.org\/10.1111\/epi.17930","journal-title":"Epilepsia"},{"key":"408_CR62","doi-asserted-by":"publisher","first-page":"116174","DOI":"10.1016\/j.jpba.2024.116174","volume":"245","author":"F Pigliasco","year":"2024","unstructured":"Pigliasco, F., Cafaro, A., Barco, S., et al. (2024). Innovative LC-MS\/MS method for therapeutic drug monitoring of Fenfluramine and Cannabidiol in the plasma of pediatric patients with epilepsy. Journal of Pharmaceutical and Biomedical Analysis, 245, 116174. https:\/\/doi.org\/10.1016\/j.jpba.2024.116174","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"408_CR63","doi-asserted-by":"publisher","unstructured":"Holtkamp, M., May, T.W., Berkenfeld, R. et al. (2024) Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. Clin Epileptol,37, 118\u2013139. https:\/\/doi.org\/10.1007\/s10309-024-00663-y https:\/\/doi.org\/10.1007\/s10309-024-00663-y","DOI":"10.1007\/s10309-024-00663-y"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00408-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:47:21Z","timestamp":1757267241000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00408-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00408-w","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MH reports no conflicts of interest.TM receives speaker\u2019s honoraria from Jazz Pharma, UCB, and Angelini Pharma.KAK received speaker\u2019s honoraria from Biocodex, Desitin, Eisai, Jazz Pharmaceuticals, and UCB Pharma.SK received speaker\u2019s honoraria from Bial, Destin Arzneimittel, Eisai, Jazz Pharma, Merck Serono, and UCB.FvP received personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, UCB Pharma, Nutricia Milupa GmbH, Neuraxpharm, and Bial.GK received speaker\u2019s honoraria from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, UCB Pharma, Neuraxpharm, Stada Arzneimittel, Precisis GmbH, and Alexion Pharmaceuticals.II received personal fees from Angelini Pharma, Jazz Pharmaceuticals, and Precisis.FR received personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Dr. Sch\u00e4r Deutschland GmbH, Eisai Pharma, Jazz Pharma, Nutricia Milupa GmbH, Stoke Therapeutics, Takeda, UCB Pharma and Vitaflo Deutschland GmbH. Research support from the European Union (EU-FP7), German Research Foundation (DFG), Federal State of Hesse, Germany, Detlev Wrobel Fonds for Epilepsy Research, Reiss-Stiftung, Dr. Senckenbergische-Stiftung, Kassel-Stiftung, Ernst Max von Grunelius-Stiftung, Chaja-Stiftung.SSB received personal fees and grants from Angelini Pharma, Biocodex, Biomarin, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, and UCB Pharma.AS received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Longboard, Neuraxpharm, Stoke Therapeutics, Takeda, UCB Pharma, and UNEEG Medical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics committee approval was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Waived due to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"49"}}